logo
2025 SUPER BOWL ADS FUMBLE AGAIN: How Ignoring Women Cost Brands ROI For the 12th Year

2025 SUPER BOWL ADS FUMBLE AGAIN: How Ignoring Women Cost Brands ROI For the 12th Year

Yahoo25-02-2025

ABX Advertising Benchmark Index™ and ANA SeeHer™, partners and co-developers of GEM®, (the Gender Equality Measure), today announced that Super Bowl 2025 ads were, once again, less effective than regular brand ads airing in the prior 12-month period. Amazingly, this trend has held true for 12 years (except for 2020 during Covid). Could the fact that these ads had little appeal to women be a reason for these declining scores?
Super Bowl Ads vs Same Brand Ads Prior 12 Months
Super Bowl Average ABX Index Scores by KPI
GEM vs ABX Reputation Index
New York, Feb. 25, 2025 (GLOBE NEWSWIRE) -- – ABX Advertising Benchmark Index™ and ANA SeeHer™, partners and co-developers of GEM®, (the Gender Equality Measure), today announced that Super Bowl 2025 ads were, once again, less effective than regular brand ads airing in the prior 12-month period. Amazingly, this trend has held true for 12 years (except for 2020 during Covid). Could the fact that these ads had little appeal to women be a reason for these declining scores? (See chart below)
ABX Advertising Benchmark Index™ is a leading advertising effectiveness company that has measured half-a-million ads, across all media types, globally to date. SeeHer, launched by the Association of National Advertisers (ANA) in 2016, is the leading global movement to eliminate gender bias in advertising, marketing, media, and entertainment. GEM® scores are highly correlated to improving brand health and increasing sales. It is considered the 'gold standard' for measuring gender bias worldwide.
This chart shows that regular ads have outperformed Super Bowl ads for the same brandsover the last 12 months, for the past 12 years.
Only 11% of Super Bowl 2025 ads were above the ABX Index™ TV norm of 108.5, 37% were at norm, and 52% were below norm. Why are so many Super Bowl ads, at $8 million a pop, missing the mark?
The ABX KPI scores below provide some insights on where these ads go wrong. While Super Bowl ads are more Likeable and Re-watchable than regular brand ads, they fall short in Brand Reputation, Purchase Intent, and other Calls-to-Action. If ads don't stimulate Action or increase Reputation, are they worth $8 million to air? Here are the differences between Super Bowl and regular ads for the same brands for the prior 12-month period:
Super Bowl ads usually score high in Likeability and Watchability, but not so much inBrand Reputation, Purchase Intent and Calls-to-Action that drive sales.Clear Brand: Clear which brand is being advertisedBrand Reputation: Feel better, worse, no different about the brand after being exposed to the adPurchase Intent: As a result of seeing this ad, intend to purchaseCalls to Action: As a result of seeing this ad, any of six actions are takenLikeability: Like this ad based on a 10-point scaleSee Again: I would be willing to see this ad againSuper Bowl ads Aren't Resonating with Women Watching the Game
Women have always been football fans. However, advertising has not acknowledged female fans, nor appealed to them, which is likely a contributing factor of low Super Bowl ad scores.
Women's economic impact this year extended beyond viewership. ABX data showed that 40% of each female viewer spent an average of $30 or more on Super Bowl-related purchases such as food, party supplies, and merchandise. Beyond game day, women wield $31.5 trillion in purchasing power and influence 85% of consumer decisions. While viewership from female fans should emphasize the growing importance of this demographic, women (female characters) are often absent, overshadowed, or inauthentically portrayed in ads.
Female Representation in Ads Fall Short
For this part of the analysis, we leveraged nine years of Super Bowl creative testing results and trends from the ABX Index and GEM® metric. In 2025, women were present in 81% of Super Bowl ads, a drop of 10 points from 2024. Only one ad had a solo female character. Thirteen percent featured only male characters, all of which were at or below the ABX TV norm. Eighty percent of ads featured both male and female characters.
While women were present in Super Bowl ads, they didn't see themselves represented accurately. The Gender Equality Measure (GEM®) for female characters was rated lower by female respondents than by male respondents.
Missing the Mark with Female Fans is a Missed Opportunity
Not targeting female fans correlates with weaker purchase intent among women. For Super Bowl ads, the ABX Purchase Intent Index was only 87 for women compared to 124 for men. Improving the portrayal of women is highly correlated with improved Reputation and Call-to-Action Scores (includes website visits, search, purchases, recommendations).
As explained below, as the GEM score increases, so do Reputation and CTAs.
The chart above shows that for every GEM® point score improvement, Brand Reputation improves by 1.7 points, for a 70% increase. The same is true with Calls-To-Action. As GEM® increases, CTAs improve by 0.5 points, or 25%. The measure of overall effectiveness, the ABX Index, improves 0.4, or 20%, for every GEM® point of improvement for brands whose ads accurately portrayed women vs. those that did not.
Conclusion
Super Bowl advertisers continue to miss the mark on creative, which significantly reduces the impact of their substantial investment. And despite the increasing interest and viewership by women, Super Bowl ads fail to resonate with them. For Super Bowl and non-Super Bowl ads, brands can benefit by prioritizing inclusivity and authenticity, leveraging best practices to optimize their investment and connect with one of the most influential consumer segments in the market …. WOMEN!
Contributors
Gary Getto, President & Co-Founder, ABX Advertising Benchmark IndexGary@adbenchmark.com
Yatisha Forde, Sr. Director, Insights & Thought Leadership, SeeHeryforde@ana.net
Press Inquiries:Angela Jeffrey, VP Brand Management, ABXangie@adbenchmark.com
Contact us HereAbout GEM®
GEM®, spearheaded by SeeHer and ABX Advertising Benchmark Index, is a globally renowned ESOMAR (European Society for Opinion and Marketing Research) award-winning effectiveness measurement methodology. GEM® evaluates gender portrayals in advertising and content and is highly correlated to improving brand health, as well as increasing sales. Advertisements delivering high GEM® scores have yielded double-digit increases in brand reputation, brand choice, purchase intent, calls to action, and brand loyalty. Moreover, ads with elevated GEM® scores have been correlated with driving significant sales lifts across genders, races/ethnicities, and generations, up to 10X higher than ads with low GEM® scores.
About Advertising Benchmark Index
ABX Advertising Benchmark Index (www.adbenchmark.com) is an ANA SeeHer partner and co-developer of GEM®. It is a techno-research company focused on driving ROAS & ROI through its Global Integrated Single Solution. Marketers, through the ABX Global Multimedia Platform, can evaluate the effectiveness of all their creative across all media types and channels, and against their competitors, in 75+ countries. ABX has evaluated half-a-million live, in-market ads through its syndicated system, and offers a wide variety of standard and customized solutions.
About SeeHer
SeeHer is the leading global movement to eliminate gender bias in marketing, media, and entertainment. Launched in 2016 by the Association of National Advertisers (ANA), SeeHer's coalition of leaders is committed to setting the gender equality agenda for the industry and driving growth for their businesses. To help its members benchmark success and become catalysts for change, SeeHer spearheaded the development of the Gender Equality Measure (GEM®), the first research methodology that quantifies gender bias in ads and programming. A winner of the prestigious ESOMAR Research Effectiveness Award, GEM® is the global measurement standard, proving that content accurately portraying women and girls dramatically increases purchase intent and brand reputation. SeeHer's suite of training and resources, including GEM®, enables marketers to prioritize best practices as part of an always-on approach to driving growth. The movement includes the following vertical expertise: SeeHer in Sports, SeeHer Entertainment, SeeHer Health, and the SeeHer Media Task Force. Visit SeeHer.com to join the movement and follow SeeHer on LinkedIn and Instagram.
Sources: ABX Advertising Benchmark Index, SeeHer, (Gender Equality Measure) 2017-2025 Super Bowl Ad Analysis
Attachments
Super Bowl Ads vs Same Brand Ads Prior 12 Months
Super Bowl Average ABX Index Scores by KPI
GEM vs ABX Reputation Index
CONTACT: Angela Jeffrey, VP Brand Management, ABX angie@adbenchmark.comSign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stifel Announces Victor Nesi to Retire as Co-President and Head of Institutional Group; Joins Board of Directors
Stifel Announces Victor Nesi to Retire as Co-President and Head of Institutional Group; Joins Board of Directors

Yahoo

time29 minutes ago

  • Yahoo

Stifel Announces Victor Nesi to Retire as Co-President and Head of Institutional Group; Joins Board of Directors

ST. LOUIS, June 11, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that Victor Nesi, Co-President and Head of the Institutional Group, will retire from his day-to-day operating responsibilities effective July 1, 2025, after 16 years of distinguished service. Mr. Nesi will, however, continue to serve the firm, simultaneously joining its Board of Directors. 'Victor has been instrumental in building the platform we have today,' said Ronald J. Kruszewski, Chairman and CEO of Stifel. 'The transformation of our Institutional Group under his guidance is one of the great success stories in our firm's history. His strategic vision, leadership, and relentless focus on client service elevated Stifel into a major player in the investment banking world. On a personal level, I am grateful for Victor's partnership and steady counsel, and I am thrilled he will continue to contribute as a valued member of our Board.' Mr. Nesi joined Stifel in 2009, at a formative moment for the firm's Institutional Group. Under his stewardship, the Institutional Group's overall revenue grew from $391 million in 2008 to a peak of $2.2 billion in 2021, while extending its reach across geographies, products, and capabilities. Investment banking revenue alone climbed 20x during this time from $84 million to a record $1.6 billion. In 2024, the Institutional Group reported $1.6 billion in revenue, which represents a more than fourfold increase since Mr. Nesi's arrival. 'Importantly, Victor has also ensured that the Institutional Group is well-positioned for continued success,' added Mr. Kruszewski. 'He has put in place a seasoned leadership team and a strong organizational structure designed to carry forward the culture that he helped establish.' 'It has been an honor and privilege to help grow Stifel into a premier full-service investment bank,' said Mr. Nesi. 'Our success is a direct reflection of the extraordinary people of Stifel – their talent, relentless drive, and unwavering commitment have made everything possible. Together, we have built something enduring with the momentum to achieve even greater things. Consequently, I believe this is the appropriate time for me to step back and allow the next generation of leaders to continue driving our firm forward. I am still energized and eager for new challenges and I look forward to supporting Stifel's continued success in my new role on the Board.' Mr. Nesi's career in investment banking spans four decades. Before coming to Stifel, he held several leadership positions at Merrill Lynch, including Head of Americas Investment Banking. He has also worked as an investment banker at Salomon Brothers and Goldman Sachs and practiced corporate and securities law at Shea & Gould. Stifel Company InformationStifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel's broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Stifel Independent Advisors, LLC. The Company's broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company's website at For global disclosures, please visit Media ContactNeil Shapiro, +1 (212) 271-3447shapiron@ Investor Relations Contact Joel Jeffrey, +1 (212) 271-3610 investorrelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Yahoo

timean hour ago

  • Yahoo

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Yahoo

timean hour ago

  • Yahoo

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store